CAPR — CAPRICOR THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1133869 ·
Last close
$7.83
Market Cap
$455.23M
52W High
$40.37
52W Low
$2.96
ADV30
3,804,197
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -42,945,620 | -40,733,654 | 368,735,835 | 20,935,187 | 122,516,945 |
| Mar 2026 | 0 | — | -36,772,853 | -33,941,345 | 326,283,517 | 105,421,484 | 47,580,884 |
| Dec 2025 | 0 | — | -29,156,008 | -30,170,914 | 355,949,294 | 287,847,312 | 50,157,149 |
| Sep 2025 | 0 | — | -26,284,040 | -24,570,647 | 126,438,207 | 19,510,383 | 42,570,952 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-92,632,632
Investing CF
$-81,052,988
Financing CF
$250,312,601
CapEx
$-21,330,892
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.32
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-338,819,830
Inventory
—
Receivables
—
ST Investments
$173,188,430
EBIT TTM
$-113,786,526
Pretax Income TTM
$-114,592,097
Interest Exp TTM
—
Analysts
4
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -108,142,130 | -105,043,946 | 355,949,294 | 50,157,149 | 305,792,145 | -69,811,261 |
| Dec 2024 | 22,270,465 | -42,563,242 | -40,467,186 | 170,481,086 | 25,018,750 | 145,462,336 | -39,995,742 |
| Dec 2023 | 25,178,066 | -24,077,859 | -22,287,542 | 58,734,327 | 36,132,860 | 22,601,467 | -25,596,545 |
| Dec 2022 | 2,551,469 | -29,697,383 | -29,019,532 | 50,094,910 | 38,308,816 | 11,786,094 | 4,916,637 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-114,593,697
OpCashFlow TTM
—
Assets (Latest)
$326,283,517
Forward EPS
$-1.48
Max Pain — expiry 2026-10-16
max pain strike: $9.00 · spot: $7.83 · call oi: 11,601 · put oi: 6,253
Expected Move to 2026-10-16:
±$0.88
(11.17%) —
implied range
$6.95 –
$8.70
· ATM straddle on $8.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PRTA | PROTHENA CORP PUBLIC LTD CO | $453.82M | $8.84 | — |
| IBO | IMPACT BIOMEDICAL INC. | $458.24M | $4.25 | — |
| DMAC | DiaMedica Therapeutics Inc. | $449.20M | $8.33 | — |
| OCS | Oculis Holding AG | $463.10M | $8.34 | — |
| KMDA | KAMADA LTD | $466.30M | $8.08 | — |
News headlines (Yahoo Finance, 1h cache)
CAPR Stock Rises Nearly 5% As Capricor Presents Heart Data For Deramiocel Ahead Of November FDA Decision
2026-10-07 23:30 · Yahoo
Capricor Highlights Two-Year Deramiocel Data as FDA Decision Nears
2026-10-07 23:02 · Yahoo
Capricor’s DMD Therapy Shows 76% Slower Upper-Limb Decline — This Analyst Expects A Complete Response Letter In November
2026-10-05 15:59 · Yahoo
CAPR Stock Clocks Best Day In Over A Month As 24-Month Duchenne Data Airs At Medical Conference In Japan
2026-10-01 00:02 · Yahoo
Why Did CAPR Stock Jump 20% After-Hours Today?
2026-09-30 01:24 · Yahoo
Capricor Therapeutics (CAPR) Stock Gets Fair Value Boost After Deramiocel Analyst Revisions
2026-09-23 13:19 · Yahoo
Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress
2026-09-17 12:30 · Yahoo
Sector Update: Healthcare Stocks Advance Late Afternoon
2026-09-01 19:46 · Yahoo
Capricor Therapeutics shares rise 2.5% following August FDA update
2026-09-01 10:55 · Yahoo
Why Is CAPR Stock Rising Today? Piper Sandler Says Risk-Reward Favors Owning Stock Into FDA Decision
2026-09-01 10:52 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.